Nomura Asset Management Co. Ltd. Buys 4,687 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Share on StockTwits

Nomura Asset Management Co. Ltd. lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,287 shares of the medical research company’s stock after acquiring an additional 4,687 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Thermo Fisher Scientific were worth $20,217,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of TMO. Orser Capital Management LLC increased its holdings in Thermo Fisher Scientific by 3.6% in the fourth quarter. Orser Capital Management LLC now owns 11,586 shares of the medical research company’s stock worth $3,766,000 after purchasing an additional 406 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in Thermo Fisher Scientific by 21.6% in the fourth quarter. Quadrant Capital Group LLC now owns 6,068 shares of the medical research company’s stock worth $1,931,000 after purchasing an additional 1,078 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Thermo Fisher Scientific by 17.1% in the fourth quarter. Victory Capital Management Inc. now owns 177,503 shares of the medical research company’s stock worth $55,592,000 after purchasing an additional 25,893 shares in the last quarter. Grimes & Company Inc. increased its holdings in Thermo Fisher Scientific by 21.4% in the fourth quarter. Grimes & Company Inc. now owns 1,331 shares of the medical research company’s stock worth $433,000 after purchasing an additional 235 shares in the last quarter. Finally, IndexIQ Advisors LLC increased its holdings in Thermo Fisher Scientific by 28.7% in the fourth quarter. IndexIQ Advisors LLC now owns 15,390 shares of the medical research company’s stock worth $5,000,000 after purchasing an additional 3,428 shares in the last quarter. Institutional investors and hedge funds own 87.65% of the company’s stock.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $333.02, for a total value of $9,990,600.00. Following the completion of the transaction, the chief executive officer now owns 304,946 shares in the company, valued at approximately $101,553,116.92. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $348.00, for a total value of $870,000.00. Following the completion of the transaction, the chief financial officer now owns 37,989 shares of the company’s stock, valued at approximately $13,220,172. The disclosure for this sale can be found here. In the last three months, insiders sold 97,500 shares of company stock valued at $33,044,350. 0.44% of the stock is currently owned by insiders.

TMO stock traded down $13.79 during midday trading on Thursday, hitting $339.01. The company’s stock had a trading volume of 765,144 shares, compared to its average volume of 1,951,481. The stock’s 50-day moving average price is $338.78 and its 200 day moving average price is $321.82. The company has a quick ratio of 1.69, a current ratio of 2.32 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1 year low of $250.21 and a 1 year high of $356.42. The stock has a market cap of $138.77 billion, a price-to-earnings ratio of 37.26, a PEG ratio of 2.38 and a beta of 1.04.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 22nd. The medical research company reported $2.94 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.15. Thermo Fisher Scientific had a return on equity of 17.25% and a net margin of 14.31%. The firm had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6.18 billion. During the same quarter in the prior year, the firm earned $2.81 EPS. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 11.92 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend is Friday, June 12th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 7.13%.

A number of equities research analysts have weighed in on the company. Argus reiterated a “positive” rating and issued a $370.00 target price on shares of Thermo Fisher Scientific in a report on Monday, February 24th. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $345.00 to $315.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Wells Fargo & Co raised their price objective on Thermo Fisher Scientific from $300.00 to $340.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 21st. Needham & Company LLC raised their price objective on Thermo Fisher Scientific from $341.00 to $383.00 in a research note on Thursday, April 23rd. Finally, Robert W. Baird raised their price objective on Thermo Fisher Scientific from $340.00 to $341.00 and gave the company an “outperform” rating in a research note on Wednesday, March 4th. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $349.31.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: What is a Reverse Stock Split?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply